Cargando…
Intravenous tPA Therapy Does Not Worsen Acute Intracerebral Hemorrhage in Mice
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH). Surprisingly, however, the assumption that tPA will worsen I...
Autores principales: | Foerch, Christian, Rosidi, Nathanael L., Schlunk, Frieder, Lauer, Arne, Cianchetti, Flor A., Mandeville, Emiri, Arai, Ken, Yigitkanli, Kazim, Fan, Xiang, Wang, Xiaoying, van Leyen, Klaus, Steinmetz, Helmuth, Schaffer, Chris B., Lo, Eng H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568130/ https://www.ncbi.nlm.nih.gov/pubmed/23408937 http://dx.doi.org/10.1371/journal.pone.0054203 |
Ejemplares similares
-
Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage
por: Schlunk, Frieder, et al.
Publicado: (2016) -
Lower doses of isoflurane treatment has no beneficial effects in a rat model of intracerebral hemorrhage
por: Esposito, Elga, et al.
Publicado: (2013) -
tPA or not tPA? Lysis therapy in the setting of COVID‐19 and ECMO
por: Cromartie, Anjelica, et al.
Publicado: (2022) -
Neuroprotective effect of neuroserpin in non-tPA-induced intracerebral hemorrhage mouse models
por: Li, Wei, et al.
Publicado: (2017) -
Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke–no influence on functional outcome and blood–brain barrier disruption
por: Cai, Aijia, et al.
Publicado: (2013)